Rational Design of live-attenuated vaccines for flaviviruses
黄病毒减毒活疫苗的合理设计
基本信息
- 批准号:10397675
- 负责人:
- 金额:$ 23.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelAntiviral AgentsAttenuatedAttenuated VaccinesChimeric ProteinsClinical TrialsCommunicable DiseasesComplementComplementary DNAConsensusConsensus SequenceConserved SequenceDataDevelopmentDiseaseEncephalitisEngineeringFlavivirusFlavivirus InfectionsFutureGenesGenomic SegmentGlycineGoalsGrowthHealthHumanHydrophobic InteractionsHydrophobicityImmunizationImpairmentIn VitroIncidenceIndividualInfectionJapanese EncephalitisJapanese encephalitis virusKnowledgeLeadLengthMembrane FusionModelingMovementMusMutagenesisMutateMutationPathogenesisPathogenicityPatternPeptidesPhenotypeProcessPublicationsReporterSafetySerial PassageSideStandardizationStructureSurfaceSystemTertiary Protein StructureTestingThe SunVaccine DesignVaccinesViralViral Hemorrhagic FeversVirionVirulenceVirusWest Nile virusYangYellow FeverYellow fever virusZoonosesattenuationbasedesigndimerdisorder controlenv Gene Productsflexibilitygenomic locushuman diseaseimmunogenicityin vivolate endosomemonomermouse modelmutantprematurerational designreceptorreceptor bindingreverse geneticssuccesstissue tropismtransmission processvaccine candidatevaccinology
项目摘要
Project summary:
The objective of the proposed study is to develop broadly effective attenuation strategies for the rational design
of live-attenuated vaccines (LAVs) against flaviviruses. Pathogenic flaviviruses cause severe human diseases
such as hemorrhagic fever and encephalitis. The use of two legacy vaccines, yellow fever virus (YFV) 17D and
Japanese encephalitis virus SA14-14-2, has demonstrated how immunization can be an efficient strategy for
disease control. However, the empirical approach used for the development of these LAVs has proven ineffective
in producing candidate LAVs for other flaviviruses, thereby demanding new strategies for rational vaccine design.
Previously, the rational design of flavivirus LAVs was based on the introduction of mutations that lead to
attenuated phenotypes observed in the two legacy vaccines and other attenuated mutants. This failed to produce
broadly effective attenuation concepts, because the mutagenesis targets lacked conserved sequences or
interacted with diverse host molecules. A major challenge in designing LAVs is the field's limited knowledge of
flavivirus virulence mechanisms. Target genes that contain consensus sequences, functionally important for the
virulence of different flaviviruses, are yet to be identified. In this study, the PI will develop two attenuation
strategies by interfering with the interdomain movements of flavivirus envelope (E) proteins. Interdomain
movements of E proteins are universally conserved mechanisms in all flaviviruses and critical for viral membrane
fusion and virion assembly; they are controlled by highly conserved sequences in two sets of interdomain
peptides, the envelope protein domain I (EDI) – envelope protein domain II (EDII) hinge and the EDI – envelope
protein domain III (EDIII) linker. The central hypothesis is that conserved residues in the interdomain
peptides are functionally important for flavivirus virulence, regardless of their tissue tropism and disease
pathogenesis. To remove virulence determinants in the two interdomain peptides, mutagenesis analyses will be
conducted in the following two specific aims: In Aim 1, highly conserved hydrophobic residues will be mutated to
interfere with the hydrophobic interactions that contribute to EDI-EDII hinge structure and functions; in Aim 2,
the structures and functions of EDI-EDIII linker will be disrupted by removing functionally important side-chains
of conserved residues and inserting additional glycine/prolin residues to increase peptide flexibility. Broadly
effective attenuation strategies will be developed by engineering selected mutations into the full-length
complementary DNA infectious clones of two model flaviviruses, West Nile virus and YFV, and then
demonstrating the loss of virulence in respective mouse models. The completion of the proposed study will lead
to an advancement in knowledge regarding the functional importance of the EDI-EDII hinge and EDI-EDIII linker
interdomain regions for flavivirus virulence. The results of this study are expected to provide the basis for broadly
effective attenuation strategies for pathogenic flaviviruses and facilitate the rational design of future candidate
flavivirus LAVs.
项目概要:
建议研究的目的是为合理设计开发广泛有效的衰减策略
抗黄病毒减毒活疫苗(LAV)。致病性黄病毒引起严重的人类疾病
如出血热和脑炎。使用两种传统疫苗,黄热病病毒(YFV)17 D和
日本脑炎病毒SA 14 -14-2,已经证明了免疫接种如何成为一种有效的策略,
疾病控制。然而,用于开发这些LAV的经验方法已被证明是无效的
在生产其他黄病毒的候选LAV中,因此需要合理疫苗设计的新策略。
以前,黄病毒LAV的合理设计是基于引入突变,
在两种传统疫苗和其他减毒突变体中观察到的减毒表型。但这并没有产生
广泛有效的减毒概念,因为诱变靶缺乏保守序列或
与不同的宿主分子相互作用LAV设计的一个主要挑战是该领域对以下方面的知识有限:
黄病毒毒力机制包含共有序列的靶基因,对基因组的功能重要,
不同黄病毒的毒力尚待鉴定。在这项研究中,PI将开发两个衰减
通过干扰黄病毒包膜(E)蛋白的结构域间运动的策略。域间
E蛋白的运动是所有黄病毒中普遍保守的机制,并且对于病毒膜至关重要。
融合和病毒体装配;它们由两组结构域间的高度保守序列控制
多肽,包膜蛋白结构域I(EDI)-包膜蛋白结构域II(EDII)铰链和EDI -包膜蛋白结构域II(EDII)铰链。
蛋白质结构域III(EDIII)接头。核心假设是,结构域间的保守残基
肽对于黄病毒的毒力具有重要的功能,无论它们的组织嗜性和疾病
发病机制为了去除两个结构域间肽中的毒力决定簇,将进行诱变分析。
在以下两个具体目标中进行:在目标1中,将高度保守的疏水残基突变为
干扰有助于EDI-EDII铰链结构和功能的疏水相互作用;在目的2中,
EDI-EDIII接头的结构和功能将通过去除功能上重要的侧链而被破坏
保守残基和插入额外的甘氨酸/脯氨酸残基,以增加肽的灵活性。广泛
将通过将选择的突变工程化到全长
两种模式黄病毒,西尼罗河病毒和YFV的互补DNA感染性克隆,然后
证明在各自的小鼠模型中丧失了毒力。拟议研究的完成将导致
关于EDI-EDII铰链和EDI-EDIII接头的功能重要性的知识的进步
黄病毒毒力的结构域间区域。这项研究的结果预计将提供广泛的基础,
病原性黄病毒的有效减毒策略,并促进未来候选疫苗的合理设计
黄病毒LAVs
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yan-Jang Huang其他文献
Yan-Jang Huang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 23.78万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 23.78万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 23.78万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 23.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 23.78万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 23.78万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 23.78万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 23.78万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 23.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 23.78万 - 项目类别: